“The benefits of using the drug among children 5-11 years old outweigh the risks, especially among those children who have concomitant diseases that increase the risk of severe illness,” the EU regulator said in a press release.
It is noted that the dose for children in the age group 5-11 years old will be lower than for citizens aged 12 years and older - 10 mcg instead of 30 mcg.
Earlier, the Canadian Ministry of Health approved the use of Pfizer and BioNTech anti-coronavirus vaccines for children aged 5-11 years.
Prior to that, mass vaccination against COVID-19 of children aged 5-11 began in Vienna.